Remdesivir for the Treatment of Covid-19 - Preliminary Report.

By Z. McCaw, D. H. Kim, Lee-Jen Wei. New England Journal of Medicine, 2020

1,429 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

COVID-19 neutralizing antibodies predict disease severity and survival (2020, neutral): “Remdesivir, a nucleotide analog active against SARS-CoV-2, has shown modest benefit in severe COVID-19 cases by improving time to recovery (Beigel et al., 2020; Wang et al., 2020b).”
Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial. (2020, neutral): “Hydroxychloroquine/chloroquine 22 (11) 16 (8) 89 (45)”
COVID-19 and multisystem inflammatory syndrome in children and adolescents (2020, neutral): “110 However, because remdesivir inhibits the actively replicating virus and most children with MISC are not in the acute phase of illness and the virus is not detectable by PCR, the role of remdesivir in the treatment of MISC is limited.”
Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial. (2020, background): “Time from symptoms onset to randomization, median (IQR), d 62 10 (7-13) 66 10 (8-13)”